CRBP Stock Price, Corbus Pharmaceuticals Holdings Quote, Chart

Market Summary

USD45.00-0.92

Delayed

-2.00%

CRBP Stock Price

View Fullscreen

CRBP RSI Chart

CRBP Valuation

Market Cap

480.9M

Price/Earnings (Trailing)

-14.25

Price/Sales (Trailing)

481.06

Price/Free Cashflow

-16.61

CRBP Price/Sales (Trailing)

CRBP Profitability

Return on Equity

-34.81%

Return on Assets

-26.85%

Free Cashflow Yield

-6.02%

CRBP Fundamentals

CRBP Revenue

Revenue (TTM)

881.7K

CRBP Earnings

Earnings (TTM)

-33.8M

Earnings Growth (Yr)

61.12%

Earnings Growth (Qtr)

14%

Breaking Down CRBP Revenue

Last 7 days

4.7%

Last 30 days

21.1%

Last 90 days

94.8%

Trailing 12 Months

351.8%

How does CRBP drawdown profile look like?

CRBP Financial Health

Current Ratio

4.69

CRBP Investor Care

Shares Dilution (1Y)

153.53%

Diluted EPS (TTM)

-4.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	2.8M	2.7M	1.5M	1.2M
2020	36.0M	7.2M	5.9M	3.9M
2019	5.8M	34.0M	35.5M	36.1M
2018	2.1M	2.6M	2.9M	4.8M
2017	2.8M	2.8M	2.8M	2.4M
2016	964.1K	1.3M	1.6M	1.9M
2015	0	0	0	648.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Corbus Pharmaceuticals Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	moran sean f.	acquired	53,610	30.00	1,787	chief financial officer
Mar 08, 2024	cormorant asset management, lp	bought	13,314,200	44.3806	300,000	-
Mar 07, 2024	cormorant asset management, lp	bought	10,013,400	40.0535	250,000	-
Feb 27, 2024	smethurst dominic	acquired	-	-	50,000	chief medical officer
Feb 12, 2024	cohen yuval	acquired	-	-	73,947	chief executive officer
Feb 12, 2024	moran sean f.	acquired	-	-	40,176	chief financial officer
Feb 02, 2024	cormorant asset management, lp	bought	14,250,000	19.00	750,000	-
Jan 26, 2024	cohen yuval	acquired	35,679	4.97	7,179	chief executive officer
Jan 26, 2024	cormorant asset management, lp	bought	9,111,940	32.2396	282,632	-
Jan 26, 2024	holmer alan f	acquired	3,126	4.97	629	-

Which funds bought or sold CRBP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	33.00	39.00	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	1,271,380	1,271,380	-%
May 15, 2024	Walleye Capital LLC	new	-	5,202,600	5,202,600	0.01%
May 15, 2024	Hudson Bay Capital Management LP	new	-	1,687,320	1,687,320	0.01%
May 15, 2024	Sio Capital Management, LLC	sold off	-100	-906,000	-	-%
May 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	new	-	1,373,400	1,373,400	0.19%
May 15, 2024	Tower Research Capital LLC (TRC)	added	45.04	60,540	67,728	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	added	274	5,870,600	6,121,950	0.12%
May 15, 2024	Cormorant Asset Management, LP	new	-	79,461,000	79,461,000	3.49%
May 15, 2024	Ghost Tree Capital, LLC	new	-	2,234,360	2,234,360	0.62%

Are Funds Buying or Selling CRBP?

Are funds buying CRBP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRBP

No. of Funds

Unveiling Corbus Pharmaceuticals Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	cormorant asset management, lp	19.30%	2,025,000	SC 13G/A
Feb 28, 2024	millennium management llc	5.3%	544,276	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	7.8%	10,524,401	SC 13G
Feb 14, 2024	paradigm biocapital advisors lp	0.0%	0	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	7.5%	342,113	SC 13G/A
Feb 12, 2024	ra capital management, l.p.	4.1%	430,182	SC 13G
Feb 12, 2024	adage capital partners gp, l.l.c.	7.70%	796,392	SC 13G
Feb 09, 2024	integrated core strategies (us) llc	4.0%	412,321	SC 13G
Feb 05, 2024	paradigm biocapital advisors lp	9.0%	399,658	SC 13G
Feb 05, 2024	cormorant global healthcare master fund, lp	14.27%	1,475,000	SC 13G

Recent SEC filings of Corbus Pharmaceuticals Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 08, 2024	144	Notice of Insider Sale Intent
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	8-K	Current Report
Apr 10, 2024	DEFA14A	DEFA14A
Apr 02, 2024	ARS	ARS
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Corbus Pharmaceuticals Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Corbus Pharmaceuticals Holdings Inc News

Latest updates

Corbus Pharmaceuticals Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-	-	-	97.00	137	648	658	1,231	286	1,762	2,574	2,590	29,095	1,886	1,927	1,091	854	950	-	796	350	1,294
Operating Expenses	-	9,998	-	13,973	16,838	16,062	21,471	35,205	38,425	31,647	29,764	27,686	27,389	28,408	19,518	15,989	13,247	-	-	-	-	-
S&GA Expenses	-	226	-	5,277	5,572	5,341	5,360	7,682	7,739	7,699	6,276	5,534	5,208	6,625	3,737	3,181	2,988	3,050	-	-	-	-
R&D Expenses	-	380	-	8,696	11,265	10,721	16,110	27,523	30,686	23,948	23,488	22,152	22,181	21,784	15,781	12,808	10,260	-	-	-	-	-
Interest Expenses	-Infinity%	-390	-	-391	-401	-646	-684	-454	13.00	102	151	293	4.00	2.00	2.00	5.00	937*	-	-	-	-	-
Net Income	-Infinity%	-10,260	-	-2,176	-17,138	-16,065	-8,611	-34,895	-38,105	-29,656	-26,580	-20,790	2,153	-26,234	-17,306	-14,601	-12,069	-	-	-	-	-
Net Income Margin	-42.5%	-51.76*	-36.33*	-28.57*	-28.70*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-1173.3%	-9,756	909	909	-17,476	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	344.8%	126	28.00	36.00	44.00	52.00	66.00	74.00	82.00	96.00	108	120	121	140	102	96.00	98.00	65.00	49.00	68.00	84.00	101
Current Assets	416.8%	122	24.00	31.00	38.00	46.00	60.00	67.00	75.00	88.00	100	112	112	130	92.00	85.00	88.00	55.00	38.00	58.00	75.00	93.00
Cash Equivalents	7.6%	15.00	14.00	11.00	8.00	7.00	17.00	12.00	26.00	57.00	25.00	37.00	36.00	67.00	85.00	82.00	63.00	47.00	32.00	55.00	73.00	90.00
Net PPE	-15.6%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	3.00	3.00
Liabilities	-18.2%	29.00	35.00	36.00	34.00	35.00	33.00	32.00	33.00	35.00	39.00	42.00	44.00	49.00	57.00	67.00	50.00	43.00	43.00	38.00	37.00	59.00
Current Liabilities	-18.7%	26.00	32.00	32.00	16.00	14.00	13.00	17.00	16.00	15.00	17.00	17.00	19.00	24.00	32.00	41.00	42.00	35.00	35.00	31.00	29.00	52.00
Long Term Debt	-	-	-	-	11.00	14.00	16.00	9.00	12.00	14.00	16.00	19.00	18.00	18.00	18.00	18.00	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	11.00	14.00	16.00	9.00	12.00	14.00	16.00	19.00	18.00	18.00	18.00	18.00	-	-	-	-	-	-
Shareholder's Equity	1504.3%	97.00	-6.90	0.00	10.00	16.00	33.00	42.00	49.00	61.00	69.00	78.00	77.00	92.00	45.00	29.00	48.00	23.00	6.00	30.00	47.00	42.00
Retained Earnings	-1.6%	-443	-436	-428	-418	-409	-392	-381	-372	-359	-349	-339	-337	-320	-304	-295	-260	-222	-192	-166	-145	-147
Additional Paid-In Capital	25.8%	541	430	429	428	426	425	423	422	420	419	417	414	412	349	325	309	245	199	196	193	190
Shares Outstanding	137.5%	11.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	35.00	-	-	-	31.00	-	202	-	-	-	-	-	665	-	-	-	390	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-32.6%	-7,967	-6,008	-7,176	-7,800	-15,114	-7,454	-7,245	-12,229	-10,615	-9,702	857	-17,528	-21,809	-18,224	-27,253	-26,607	-27,601	-22,561	-17,086	-16,390	10,318
Share Based Compensation	22.9%	982	799	821	823	1,026	1,269	1,346	1,513	1,592	1,793	2,599	2,507	2,580	2,341	3,631	3,348	3,138	3,098	2,978	2,817	3,089
Cashflow From Investing	-1045.6%	-98,235	10,388	10,896	8,807	5,550	11,780	-5,971	-18,696	42,962	-3,177	284	-13,098	-57,424	52.00	-56.80	-16.17	-463	-1,291	-1,194	-183	-73.61
Cashflow From Financing	5695.8%	106,583	-1,904	-820	18.00	-113	234	-110	-330	-327	768	-102	-255	60,414	21,735	46,732	43,474	42,934	753	-24.65	-191	37,927

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRBP Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 5,761,494	$ 13,388,343
General and administrative	3,861,251	3,908,682
Total operating expenses	9,622,745	17,297,025
Operating loss	(9,622,745)	(17,297,025)
Other income (expense), net:
Other income (expense), net	2,909,097	229,507
Interest expense, net	(177,015)	(678,022)
Change in fair value of derivative liability	28,568	0
Foreign currency exchange gain (loss), net	(36,676)	728
Other income (expense), net	2,723,974	(447,787)
Net loss	$ (6,898,771)	$ (17,744,812)
Earnings Per Share, Basic	$ (0.83)	$ (4.24)
Earnings Per Share, Diluted	$ (0.83)	$ (4.24)
Weighted Average Number of Shares Outstanding, Basic	8,310,508	4,181,556
Weighted Average Number of Shares Outstanding, Diluted	8,310,508	4,181,556
Comprehensive loss:
Net Income (Loss)	$ (6,898,771)	$ (17,744,812)
Other comprehensive (loss) income :
Change in unrealized (loss) gain on marketable debt securities	(326,949)	57,623
Total other comprehensive (loss) income	(326,949)	57,623
Total comprehensive loss	$ (7,225,720)	$ (17,687,189)

CRBP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 14,103,120	$ 13,723,681
Investments	106,000,091	7,182,325
Restricted cash	284,950	192,475
Prepaid expenses and other current assets	1,308,336	2,447,549
Total current assets	121,696,497	23,546,030
Restricted cash	384,950	477,425
Property and equipment, net	821,526	973,214
Operating lease right of use assets	2,841,189	3,062,920
Other assets	0	212,804
Total assets	125,744,162	28,272,393
Current liabilities:
Notes payable	189,818	300,664
Accounts payable	2,081,812	3,178,516
Accrued expenses	9,398,225	11,030,506
Derivative liability	10,882	39,450
Operating lease liabilities, current	1,477,669	1,436,723
Current portion of long-term debt	12,764,915	15,908,214
Total current liabilities	25,923,321	31,894,073
Other long-term liabilities	0	44,411
Operating lease liabilities, noncurrent	2,855,140	3,238,631
Total liabilities	28,778,461	35,177,115
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023.	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized,10,507,237 and 4,423,683 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,050	442
Additional paid-in capital	540,875,910	429,780,375
Accumulated deficit	(443,582,754)	(436,683,983)
Accumulated other comprehensive loss	(328,505)	(1,556)
Total stockholders’ equity	96,965,701	(6,904,722)
Total liabilities and stockholders’ equity	$ 125,744,162	$ 28,272,393

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFÃƒÅ¸ expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CEO	Dr. Yuval Cohen Ph.D.
WEBSITE	corbuspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	33

Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions

What is the ticker symbol for Corbus Pharmaceuticals Holdings Inc? What does CRBP stand for in stocks?

CRBP is the stock ticker symbol of Corbus Pharmaceuticals Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corbus Pharmaceuticals Holdings Inc (CRBP)?

As of Fri May 17 2024, market cap of Corbus Pharmaceuticals Holdings Inc is 480.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRBP stock?

You can check CRBP's fair value in chart for subscribers.

What is the fair value of CRBP stock?

You can check CRBP's fair value in chart for subscribers. The fair value of Corbus Pharmaceuticals Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corbus Pharmaceuticals Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRBP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corbus Pharmaceuticals Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether CRBP is over valued or under valued. Whether Corbus Pharmaceuticals Holdings Inc is cheap or expensive depends on the assumptions which impact Corbus Pharmaceuticals Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRBP.

What is Corbus Pharmaceuticals Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CRBP's PE ratio (Price to Earnings) is -14.25 and Price to Sales (PS) ratio is 481.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBP PE ratio will change depending on the future growth rate expectations of investors.